According to the data monitored by the "A-share Green Report" project, Huadong Medicine (SZ000963, stock price 397 yuan, market value of 69.7 billion yuan) Shaanxi Jiuzhou Pharmaceutical Co., Ltd., an indirect holding subsidiary, was approved in principle for the environmental impact assessment and approval of the oral liquid production line transformation project. The total investment of the project is 9 million yuan. The approval information was disclosed by the relevant regulatory authorities on November 20, 2023.
The "A-share Green Report" project was jointly launched by National Business Daily and the well-known NGO Institute of Public and Environmental Affairs (IPE) in the field of environmental protection, aiming to make the environmental information of listed companies more transparent. Based on the authoritative environmental regulatory data released by 31 provinces, municipalities and 337 prefecture-level cities**, this project screens and monitors the environmental performance of listed companies and their subsidiaries (including branches, shareholding companies and holding companies), conducts professional data analysis and in-depth interpretation, publishes AI green reports of listed companies in a timely manner with daily intelligent writing, launches weekly A-share green reports, and regularly updates the environmental risk list of listed companies.
According to the last (138th issue) A-share green weekly report, a total of 7 listed companies have recently been exposed to environmental risks.
According to the 2023 semi-annual report, Huadong Pharmaceutical's main business is commercial brokerage and ** industry, pharmaceutical manufacturing, international medical aesthetic business, and inter-segment offset, accounting for the proportion of revenue respectively. 4%、-2.39%。
Reporter Liu Zhiyuan Wei Guanhong).
Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Do so at your own risk.
National Business Daily.